Le Lézard
Classified in: Health
Subject: TDS

Evolent Health to Participate in Upcoming Investor Conferences


WASHINGTON, Aug. 22, 2019 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent"), a company providing an integrated value-based care platform to the nation's leading provider and payer organizations, today announced that Chief Executive Officer and Co-Founder Frank Williams, President and Co-Founder Seth Blackley, Chief Financial Officer John Johnson and Executive Vice President, Corporate Performance Nicky McGrane will participate in upcoming investor conferences.

 

Evolent Health Logo (PRNewsfoto/Evolent Health)

About Evolent Health
Evolent Health partners with leading provider and payer organizations to achieve superior clinical and financial results in value-based care and under full-risk arrangements. With a provider heritage and over 20 years of health plan administration experience, Evolent partners with more than 35 health care organizations to actively manage care across Medicare, Medicaid, commercial and self-funded adult and pediatric populations. With the experience to drive change, Evolent confidently stands by a commitment to achieve results. For more information, visit evolenthealth.com.

Contacts:
Bob East or Asher Dewhurst
443.213.0500
Investor Relations
[email protected]

SOURCE Evolent Health


These press releases may also interest you

at 07:05
Three major challenges poised to confront the nation's clinical laboratories, genetic test companies, and anatomic pathology laboratories will be major topics when a top-flight roster of lab experts, innovators, and lab leaders gather in New Orleans...

at 07:05
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday,...

at 07:04
Merck , known as MSD outside the United States and Canada, announced that Health Canada has granted approval of  KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the...

at 07:00
Globe Life Inc. will release First Quarter 2024 earnings after the market closes on Monday, April 22, 2024.  At that time, a copy of the Company's First Quarter 2024 earnings press release and any other financial and statistical information about...

at 07:00
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a...

at 07:00
César A. Lara, MD, introduces a groundbreaking solution for pain relief in the Tampa Bay area. Red Laser Therapy leverages the power of medical-grade red laser light to effectively address various types of pain, providing patients with a noninvasive...



News published on and distributed by: